Based on the aggregated intelligence of 120,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, Irish biotech company Elan Corp. (NYSE: ELN) has earned a respected four-star ranking. While five-star stocks have been the best performers, our data has shown that four-star stocks still outshine the market by a significant margin and shouldn't be taken lightly; conversely, low-rated stocks have woefully lagged the market average.
With that in mind, let's take a closer look at Elan's business, and see what CAPS investors are saying about the stock right now.
Elan facts
Headquarters (Founded)
Dublin, Ireland (1969)
Market Cap
$2.88 billion
Industry
Drug Delivery
TTM Revenue
$949 million
Management
CEO G. Kelly Martin
CFO Shane Cooke
Return on Capital (average last three years)
(6.4%)
Competitors
Biogen Idec (Nasdaq: BIIB),
Pfizer (NYSE: PFE)
CAPS members bullish on ELN also bullish on: Continued...
Brian D. Pacampara is an investment expert and analyst for the Motley Fool.
Be the first to read Brian D. Pacampara's column. Sign up today and receive Townhall.com delivered each morning to your inbox.